Obi Pharmaincis A Global Clinical Stage Oncology Company Based In Taiwanwith Subsidiaries In The United States And Australiafounded In 2002 By Drmichael Nchangthe Company Focuses On Developing Innovative Cancer Therapies And Is Publicly Listed On The Taipei Exchangeobi Pharma Aims To Createfirst In Classandbest In Classdrugs To Address Unmet Medical Needs In Oncology While Promoting Amade In Taiwanbrand Identity The Company Is Actively Engaged In The Research And Development Of Cancer Treatmentsincluding Obi 3424Which Is Currently In Phase Ii Clinical Trialsobi Pharma Has Also Developed Proprietary Adcantibody Drug Conjugateplatforms And Is Working On A Covid 19 Vaccinebcvaxwhich Has Received Approval For A Phase I Clinical Trialled By Chairman Kung Yee Liang And Ceo Drheidi Wangobi Pharma Employs Around 140 People And Emphasizes Employee Well Being And Developmentin 2023The Company Achieved Iso Iec 27001 Certification For Information Security Management
Bio International Convention 2025
United States
16 Jun 2025
1545
| Company Name | Obi Pharma Inc |
| Country |
Taiwan
|
| Address | N/A |
| Telephone | N/A |
| N/A |
